Literature DB >> 12525376

Predictors of end stage lung disease in systemic sclerosis.

V Steen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12525376      PMCID： PMC1754422          DOI： 10.1136/ard.62.2.97

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  19 in total

1.  Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement.

Authors:  K Kinuya; K Nakajima; S Kinuya; T Michigishi; N Tonami; K Takehara
Journal:  Ann Nucl Med       Date:  2001-04       Impact factor: 2.668

2.  Bosentan therapy for pulmonary arterial hypertension.

Authors:  Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

3.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Authors:  D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

4.  Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.

Authors:  A J MacGregor; R Canavan; C Knight; C P Denton; J Davar; J Coghlan; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-04       Impact factor: 7.580

5.  Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis.

Authors:  M Peters-Golden; R A Wise; P Schneider; M Hochberg; M B Stevens; F Wigley
Journal:  Medicine (Baltimore)       Date:  1984-07       Impact factor: 1.889

6.  Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.

Authors:  B White; W C Moore; F M Wigley; H Q Xiao; R A Wise
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

7.  Relationship between cutaneous and pulmonary involvement in systemic sclerosis.

Authors:  S Morelli; C Barbieri; A Sgreccia; L Ferrante; V Pittoni; F Conti; G Gualdi; E Polettini; O A Carlesimo; S Calvieri
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

8.  Severe organ involvement in systemic sclerosis with diffuse scleroderma.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  2000-11

9.  African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.

Authors:  E L Greidinger; K T Flaherty; B White; A Rosen; F M Wigley; R A Wise
Journal:  Chest       Date:  1998-09       Impact factor: 9.410

10.  Predictors of end stage lung disease in a cohort of patients with scleroderma.

Authors:  C Morgan; C Knight; M Lunt; C M Black; A J Silman
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103
View more
  32 in total

Review 1.  A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

Authors:  E Hachulla; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 3.  Immunomodulatory therapy for SSc: will high-intensity immunosuppression with stem cell rescue improve outcome?

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  [Clinical risk-adapted therapies in systemic sclerosis].

Authors:  G Riemekasten; D Dragun
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

5.  Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry.

Authors:  Francisco J García-Hernández; María J Castillo-Palma; Carles Tolosa-Vilella; Alfredo Guillén-Del Castillo; Manuel Rubio-Rivas; Mayka Freire; José A Vargas-Hitos; José A Todolí-Parra; Mónica Rodríguez-Carballeira; Gerard Espinosa-Garriga; Dolores Colunga-Argüelles; Norberto Ortego-Centeno; Luis Trapiella-Martínez; María M Rodero-Roldán; Xavier Pla-Salas; Isabel Perales-Fraile; Isaac Pons-Martín Del Campo; Antonio J Chamorro; Rafael A Fernández-de la Puebla Giménez; Ana B Madroñero-Vuelta; Manuel Ruíz-Muñoz; Vicent Fonollosa-Pla; Carmen P Simeón-Aznar
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

6.  An official American Thoracic Society Statement: pulmonary hypertension phenotypes.

Authors:  Raed A Dweik; Sharon Rounds; Serpil C Erzurum; Stephen Archer; Karen Fagan; Paul M Hassoun; Nicholas S Hill; Marc Humbert; Steven M Kawut; Michael Krowka; Evangelos Michelakis; Nicholas W Morrell; Kurt Stenmark; Rubin M Tuder; John Newman
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

7.  Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic.

Authors:  Pavel Jansa; Radim Becvar; David Ambroz; Tomas Palecek; Michal Tomcik; Simona Skacelova; Michael Aschermann; Ales Linhart
Journal:  Clin Rheumatol       Date:  2011-11-22       Impact factor: 2.980

8.  Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Gerald Rouleau; David Aaby; Jungwha Lee; Carrie Richardson; Jane Dematte; Rishi Agrawal; Rowland W Chang; Monique Hinchcliff
Journal:  J Rheumatol       Date:  2018-10-01       Impact factor: 4.666

Review 9.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

10.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.